Literature DB >> 12710194

Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition.

Judith S Sebolt-Leopold1, Keri Van Becelaere, Kenneth Hook, Roman Herrera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12710194     DOI： 10.1385/1-59259-380-1:31

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN： 1543-1894


× No keyword cloud information.
  3 in total

1.  A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Premal H Thaker; David P Bender; Daron Street; William P McGuire; Carolyn M Johnston; Jacob Rotmensch
Journal:  Gynecol Oncol       Date:  2015-04-14       Impact factor: 5.482

Review 2.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors:  Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal:  Drug Resist Updat       Date:  2007-05-07       Impact factor: 18.500

3.  KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.

Authors:  N Nakayama; K Nakayama; S Yeasmin; M Ishibashi; A Katagiri; K Iida; M Fukumoto; K Miyazaki
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.